Filing step-change
SKYBIOTECH · 2026-10
Quarterly observations that moved versus the prior period in 2026-10. Facts only — not a call to act.
Narrative date 2026-10-20 · Evidence medium
SKYBIOTECH Sees Gross Margin Accelerate to 45.92% in Quarterly Update, Despite Declining Marginal Operating Leverage to -102.89%.
Raw Evidence
Source observations behind the synthesis narrative.
| Metric | Value | Trend | |
|---|---|---|---|
| GROSS_MARGIN | 45.92 % | -102.89 | ▲ |
| MARGINAL_OPERATING_LEVERAGE | -102.89 % | -30.2 | ▼ |
Cite this
Source: Samhati filing step-change for SKYBIOTECH (2026-10). Observation: SKYBIOTECH Sees Gross Margin Accelerate to 45.92% in Quarterly Update, Despite Declining Marginal Operating Leverage to -102.89%. Evidence quality: medium. Not investment advice — no buy, sell, or hold recommendation. Full narrative (Pro): https://samhati.ai/pricing Page: https://samhati.ai/stock/skybiotech/q/2026-10
Other periods